Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration

Tziakas, Dimitrios; Chalikias, Georgios K.; Parissis, John; Hatzinikolaou, E.; Papadopoulos, Elias D.; Tripsiannis, Grigorios A.; Papadopoulou, Evropi; Tentes, Ioannis; Karas, S.; Chatseras, D.

doi:10.1016/j.ijcard.2003.05.013

Cited by 62 publications

(55 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the cases, however, the scores were not associated with the recurrence of ACS, which is not that surprising since the scores were designed to be used in the primary prevention [15]. Serum MMP-8 and TIMP-1 concentrations may relate with obesity, diabetes, and use of statins, ACE-inhibitors and aldosterone antagonists [25,32,33]. Unfortunately, we did not have information on the body mass indexes of the subjects.…”

Section: Discussionmentioning

confidence: 94%

The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence

Pussinen

Sarna

Puolakkainen

et al. 2013

International Journal of Cardiology

View full text Add to dashboard Cite

The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence Pussinen, Pirkko J.; Sarna, Seppo; Puolakkainen, Mirja; Öhlin, Hans; Sorsa, Timo; Pesonen, Erkki Citation for published version (APA): Pussinen, P. J., Sarna, S., Puolakkainen, M., Öhlin, H., Sorsa, T., & Pesonen, E. (2013). The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. International Journal of Cardiology, 167(2), 362-368. https://doi.org/10.1016/j.ijcard.2011.12.095 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. AbstractBackground Matrix metalloproteinase-8 (MMP-8) is involved in the breakdown of the extracellular matrix increasing the vulnerability of atherosclerotic lesions. We analyzed the diagnostic value of serum MMP-8 and tissue inhibitor of metalloproteinase-1 (TIMP-1) concentrations in acute coronary syndrome (ACS) and their prognostic value in ACS recurrence. MethodsThe population comprised 343 patients with ACS [including 108 unstable angina pectoris and 235 acute myocardial infarctions (AMI)] and 326 healthy controls. Additionally, 157 (45.8%) patients were resampled during the recovery. The ACS patients were followed up for 6 years.Results MMP-8, TIMP-1, and their molar ratio distinguished the cases from the controls; C-statistic of the multivariate model (95% CI, p-value) including the MMP-8/TIMP-1 ratio regarding its discriminating ability for AMI was 0.922 (0.893-0.950, p<0.001). After the acute phase of ACS, median MMP-8 and TIMP-1 concentrations decreased (p<0.001) by 34.5 and 28.7%, respectively, but ended up on a different level than those found in the controls. In the follow-up, acute phase and recovery period TIMP-1 concentrations associated with cardiovascular death with hazard ratios 4.31 (2.00-9.26, p<0.001) and 4.69 (1.10-20.01, p=0.037), respectively. ConclusionsThe increase of serum MMP-8 and TIMP-1 concentrations may reflect plaque instability and tissue damage. TIMP-1 concentrations are associated with poor outcome in patients with ACS. The findings may have practical implications in both diagnostics and therapeutics.

show abstract

Section: Discussionmentioning

confidence: 94%

The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence

Pussinen

Sarna

Puolakkainen

et al. 2013

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…Papadopoulos et al (57) investigated the benefits of angiotensin-converting enzyme inhibitors in the remodelling process and found that it reduced the collagenolytic activity by reducing MMP-1 levels and decreased the progression of LV dimension after MI. Tziakas et al (58) observed a significant reduction in the levels of MMP-9, TIMP-1 and IL-6 after 30 days of atorvastatin administration. This may be due to the pleiotropic effect of atorvastatin in reducing inflammatory mediators.…”

Section: Mmpi and MI In Clinical Studymentioning

confidence: 97%

Matrix metalloproteinases and myocardial infarction

Phatharajaree

Phrommintikul

Chattipakorn

2007

Canadian Journal of Cardiology

View full text Add to dashboard Cite

A cute myocardial infarction (AMI) is one of the most important health problems in many nations around the world. It may be found in many age groups, but is predominant among elderly people (1). The incidence of AMI has been increasing, possibly due to the changes in lifestyle and dietary intake that lead to an increase in coronary risk factors for cardiovascular disease.AMI has devastating consequences in the early phase, such as cardiac rupture, and in the chronic phase, such as chronic heart failure, for which the risk is mainly determined by infarct size (2). Larger infarct size induces gross morphological, histological and molecular changes of the infarcted and noninfarcted regions. These changes are known as the cardiac remodelling process. The degree of cardiac remodelling is closely related to the incidence of cardiac arrhythmias, heart failure and mortality (3). Cardiac remodelling involves changes in cardiac myocytes and in the extracellular matrix (ECM). The ECM contains a wide array of structural proteins, such as fibrillar collagen, proteoglycans and glycosaminoglycans, and serves as a reservoir for biologically active molecules. Because myocardial collagens maintain the structural integrity of adjoining myocytes and provide the means by which myocyte shortening is translated into cardiac pump function, changes in the ECM result in a loss of normal structural and functional myocardium.Matrix metalloproteinase (MMP) is a proteolytic enzyme that has been identified in the myocardium, and is likely to contribute to ECM changes and myocardial remodelling. In the past few decades, growing evidence from basic and clinical studies have demonstrated the important role of MMPs in the progression of left ventricular dimension, remodelling and mortality following AMI. In the present article, MMP expression after AMI and its role as a possible prognostic marker are reviewed. Currently available data regarding the role of MMP inhibitors as a possible novel therapeutic intervention are also discussed. Acute myocardial infarction (AMI) is currently one of the most important health problems in many countries around the world. Following AMI, many cytokines and proteolytic enzymes are released. Among these, matrix metalloproteinases (MMPs) are important proteolytic enzymes that lead to degradation of the extracellular matrix and to changes in cardiomyocytes in both infarcted and noninfarcted myocardium. This process is known as cardiac remodelling. It has been demonstrated that more than one type of MMP is present in the circulation after cardiomyocyte injury. A number of studies have demonstrated the correlations between these MMP levels and the severity of a coronary lesion, the progression of left ventricular dimension and the survival rate following AMI in both animal and human studies. MMPs have also been proposed as a possible novel prognostic indicator for myocardial infarction patients. Although the use of MMP inhibitors to improve cardiac outcome in AMI patients has been investigated, discrepancies in the re...

show abstract

“…25 Furthermore, no correlation was found between the reduction of MMP-9 and lipid reduction in those studies. This finding was in accordance with the results of our present study, in which the reduction of MMP-9 after fluvastatin treatment was independent of its lipid-lowering and antiinflammatory effects.…”

Section: Discussionmentioning

confidence: 84%

Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia

Leu

Chen

et al. 2005

Clin Cardiol

View full text Add to dashboard Cite

SummaryBackground: Interleukin-18 (IL-18), a novel proinflammatory marker, and matrix metalloproteinase-9 (MMP-9) represent the indices of plaque stability. It is unknown whether hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), which provide anti-inflammatory and endothelium protection effects, have the property of stabilizing plaque in patients with hypercholesterolemia.Hypothesis: The study was designed to investigate the influence of statin therapy in circulating IL-18, MMP-9, and endothelial function.Methods: We investigated the effects of a 12-week therapy with fluvastatin on IL-18, MMP-9, and endothelial function in patients with hypercholesterolemia.Results: Compared with placebo, fluvastatin significantly improved flow-mediated vasodilatation to hyperemia, a hallmark of endothelial function [from 3.8% (Ϫ3.9 ~ 15.2) to 5.9% (Ϫ0.3 ~ 13.2), p = 0.001], and attenuated plasma levels of high sensitivity C-reactive protein (hsCRP) [from 1.3 (0.3 7 .7) to 1.1 mg/l (0.2 ~ 3.5), p = 0.018], .2), p < 0.001], total MMP-9 (from 58 ± 46.3 to 39.4 ± 22.4 ng/dl, p = 0.023), and MMP-9 activity [from 6.4 (3.6 ~ 27) to 5.6 ng/dl (3.1 ~ 13.7)]. However, no significant correlation was found between the degree of changes in lipid profile and flow-mediated dilatation (FMD) and plasma concentration of IL-18 and MMP-9.

show abstract

Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration

Cited by 62 publications

References 29 publications

The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence

The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence

Matrix metalloproteinases and myocardial infarction

Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia

Contact Info

Product

Resources

About